• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

艾氯胺酮鼻喷雾剂治疗难治性抑郁症的疗效:一项随机对照研究的荟萃分析。

Efficacy of esketamine nasal spray for treatment-resistant depression: A meta-analysis of randomized controlled studies.

作者信息

Ouyang Yannan, Li Juan

机构信息

School of Education, The University of Queensland, Queensland, Australia.

Academic Affairs Office, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

出版信息

Medicine (Baltimore). 2025 Feb 28;104(9):e41495. doi: 10.1097/MD.0000000000041495.

DOI:10.1097/MD.0000000000041495
PMID:40020133
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11875627/
Abstract

BACKGROUND

The efficacy of esketamine nasal spray for treatment-resistant depression remains controversial. This systematic review and meta-analysis was conducted to explore the influence of esketamine nasal spray on treatment efficacy for treatment-resistant depression.

METHODS

We conducted a comprehensive search across multiple databases, including PubMed, EMbase, Web of Science, EBSCO, and Cochrane library through March 2024 for randomized controlled trials (RCTs) assessing the effect of esketamine nasal spray on the treatment efficacy of depression. This meta-analysis was performed using the random-effect model.

RESULTS

Five RCTs are included in the meta-analysis. Overall, compared with control group treatment-resistant depression, esketamine nasal spray is associated with significantly reduced MADRS scores (SMD = -3.88; 95% confidence interval [CI] = -5.71 to -2.05; P < .0001), increased response rates (RR = 1.99; 95% CI = 1.28-3.10; P = .002), decreased Sheehan Disability Scale (SMD = -3.01; 95% CI = -4.39 to -1.64; P < .0001) and PHQ-9 scores (SMD = -2.32; 95% CI = -3.51 to -1.13; P = .0001), but leads to the increase in dizziness (RR = 3.55; 95% CI = 2.37-5.32; P < .00001) and nausea (RR = 3.88; 95% CI = 2.10-7.18; P < .0001).

CONCLUSION

Esketamine nasal spray is beneficial to improve the efficacy of treatment-resistant depression.

摘要

背景

艾氯胺酮鼻喷雾剂治疗难治性抑郁症的疗效仍存在争议。本系统评价和荟萃分析旨在探讨艾氯胺酮鼻喷雾剂对难治性抑郁症治疗效果的影响。

方法

我们对多个数据库进行了全面检索,包括截至2024年3月的PubMed、EMbase、Web of Science、EBSCO和Cochrane图书馆,以查找评估艾氯胺酮鼻喷雾剂对抑郁症治疗效果的随机对照试验(RCT)。本荟萃分析采用随机效应模型进行。

结果

荟萃分析纳入了5项RCT。总体而言,与对照组治疗难治性抑郁症相比,艾氯胺酮鼻喷雾剂与蒙哥马利-艾森伯格抑郁评定量表(MADRS)评分显著降低相关(标准化均数差[SMD]=-3.88;95%置信区间[CI]=-5.71至-2.05;P<.0001),缓解率增加(RR=1.99;95%CI=1.28-3.10;P=.002),希恩残疾量表(SMD=-3.01;95%CI=-4.39至-1.64;P<.0001)和患者健康问卷-9(PHQ-9)评分降低(SMD=-2.32;95%CI=-3.51至-1.13;P=.0001),但会导致头晕(RR=3.55;95%CI=2.37-5.32;P<.00001)和恶心(RR=3.88;95%CI=2.10-7.18;P<.0001)增加。

结论

艾氯胺酮鼻喷雾剂有利于提高难治性抑郁症的治疗效果。

相似文献

1
Efficacy of esketamine nasal spray for treatment-resistant depression: A meta-analysis of randomized controlled studies.艾氯胺酮鼻喷雾剂治疗难治性抑郁症的疗效:一项随机对照研究的荟萃分析。
Medicine (Baltimore). 2025 Feb 28;104(9):e41495. doi: 10.1097/MD.0000000000041495.
2
Esketamine Nasal Spray in Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.艾氯胺酮鼻腔喷雾剂治疗重度抑郁症:随机对照试验的荟萃分析。
Clin Pharmacol Ther. 2025 Jun;117(6):1637-1649. doi: 10.1002/cpt.3555. Epub 2025 Jan 10.
3
Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment.依他佐辛鼻喷雾剂附加治疗与附加第二代抗精神病药物治疗对难治性重度抑郁症的治疗反应。
Int J Neuropsychopharmacol. 2020 Jul 29;23(7):440-445. doi: 10.1093/ijnp/pyaa034.
4
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.灵活剂量依他佐辛鼻喷雾剂联合新起始口服抗抑郁药治疗难治性抑郁症的疗效和安全性:一项随机、双盲、活性对照研究。
Am J Psychiatry. 2019 Jun 1;176(6):428-438. doi: 10.1176/appi.ajp.2019.19020172. Epub 2019 May 21.
5
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.依他佐辛鼻喷剂联合口服抗抑郁药治疗治疗抵抗性抑郁症患者预防复发的疗效:一项随机临床试验。
JAMA Psychiatry. 2019 Sep 1;76(9):893-903. doi: 10.1001/jamapsychiatry.2019.1189.
6
Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).依他佐辛鼻喷剂固定剂量联合新型抗抑郁药治疗难治性抑郁症的疗效和安全性:一项随机、双盲、阳性对照研究(TRANSFORM-1)的结果。
Int J Neuropsychopharmacol. 2019 Oct 1;22(10):616-630. doi: 10.1093/ijnp/pyz039.
7
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies.鼻内应用氯胺酮对治疗抵抗性抑郁症患者嗅觉功能和鼻腔耐受性的影响:四项多中心、随机、双盲、安慰剂对照 III 期研究的结果。
CNS Drugs. 2021 Jul;35(7):781-794. doi: 10.1007/s40263-021-00826-9. Epub 2021 Jul 7.
8
Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression.依他佐辛鼻喷剂与喹硫平治疗难治性抑郁症的比较。
N Engl J Med. 2023 Oct 5;389(14):1298-1309. doi: 10.1056/NEJMoa2304145.
9
Effects of esketamine nasal spray on depressive symptom severity in adults with treatment-resistant depression and associations between the Montgomery-Åsberg Depression Rating Scale and the 9-item Patient Health Questionnaire.依他佐辛鼻喷剂治疗成人难治性抑郁症的疗效及蒙哥马利-Åsberg 抑郁评定量表与 9 项患者健康问卷的相关性。
CNS Spectr. 2024 Jun;29(3):176-186. doi: 10.1017/S1092852924000105. Epub 2024 Apr 1.
10
Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2).依他佐辛鼻喷剂联合口服抗抑郁药治疗难治性抑郁症患者:3 期、开放标签研究(SUSTAIN-2)的长期安全性评估。
J Clin Psychiatry. 2020 Apr 28;81(3):19m12891. doi: 10.4088/JCP.19m12891.

引用本文的文献

1
Safety Profile and Suicidality Associated with the Use of Esketamine in the Treatment of Major Depressive Disorder in European Countries: An EudraVigilance Database Analysis.欧洲国家中艾司氯胺酮用于治疗重度抑郁症的安全性概况及自杀倾向:一项欧洲药品不良反应数据库分析
Pharmaceuticals (Basel). 2025 May 9;18(5):702. doi: 10.3390/ph18050702.

本文引用的文献

1
Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3.依他佐辛鼻喷剂联合口服抗抑郁药治疗老年难治性抑郁症的疗效和安全性-TRANSFORM-3。
Am J Geriatr Psychiatry. 2020 Feb;28(2):121-141. doi: 10.1016/j.jagp.2019.10.008. Epub 2019 Oct 17.
2
Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).依他佐辛鼻喷剂固定剂量联合新型抗抑郁药治疗难治性抑郁症的疗效和安全性:一项随机、双盲、阳性对照研究(TRANSFORM-1)的结果。
Int J Neuropsychopharmacol. 2019 Oct 1;22(10):616-630. doi: 10.1093/ijnp/pyz039.
3
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.依他佐辛鼻喷剂联合口服抗抑郁药治疗治疗抵抗性抑郁症患者预防复发的疗效:一项随机临床试验。
JAMA Psychiatry. 2019 Sep 1;76(9):893-903. doi: 10.1001/jamapsychiatry.2019.1189.
4
Esketamine for Treatment-Resistant Depression - First FDA-Approved Antidepressant in a New Class.艾氯胺酮用于治疗抵抗性抑郁症——首个获美国食品药品监督管理局批准的新型抗抑郁药。
N Engl J Med. 2019 Jul 4;381(1):1-4. doi: 10.1056/NEJMp1903305. Epub 2019 May 22.
5
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.灵活剂量依他佐辛鼻喷雾剂联合新起始口服抗抑郁药治疗难治性抑郁症的疗效和安全性:一项随机、双盲、活性对照研究。
Am J Psychiatry. 2019 Jun 1;176(6):428-438. doi: 10.1176/appi.ajp.2019.19020172. Epub 2019 May 21.
6
Effectiveness of Electroconvulsive Therapy in Patients With Major Depressive Disorder and Comorbid Borderline Personality Disorder.电休克治疗对伴有边缘型人格障碍的重度抑郁症患者的疗效
J ECT. 2019 Mar;35(1):44-47. doi: 10.1097/YCT.0000000000000533.
7
Electroconvulsive therapy for older adult patients with major depressive disorder: a systematic review of randomized controlled trials.老年重度抑郁症患者的电休克治疗:随机对照试验的系统评价
Psychogeriatrics. 2018 Nov;18(6):468-475. doi: 10.1111/psyg.12359. Epub 2018 Aug 2.
8
Metabolomics of Major Depressive Disorder and Bipolar Disorder: Overview and Future Perspective.重性抑郁障碍和双相情感障碍的代谢组学:概述和未来展望。
Adv Clin Chem. 2018;84:81-99. doi: 10.1016/bs.acc.2017.12.005. Epub 2018 Feb 1.
9
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.鼻腔内依他佐辛辅助口服抗抑郁药治疗难治性抑郁症的疗效和安全性:一项随机临床试验。
JAMA Psychiatry. 2018 Feb 1;75(2):139-148. doi: 10.1001/jamapsychiatry.2017.3739.
10
Cognitive dysfunction in major depressive disorder.重度抑郁症中的认知功能障碍。
Curr Opin Psychiatry. 2018 Jan;31(1):26-31. doi: 10.1097/YCO.0000000000000378.